Immunotherapy of Stage III/IV Melanoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Melanoma
Interventions
BIOLOGICAL

Melan-A ELA + Montanide

"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."

BIOLOGICAL

Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide

"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."

BIOLOGICAL

Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG

"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."

BIOLOGICAL

Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG

"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."

BIOLOGICAL

Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2

"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."

Trial Locations (2)

1011

Oncology Department, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne

1211

Division of Oncology at the Geneva University Hospital, Geneva

Sponsors
All Listed Sponsors
collaborator

Ludwig Institute for Cancer Research

OTHER

lead

Centre Hospitalier Universitaire Vaudois

OTHER